Godrej Industries to invest Rs 750 crore in chemical business expansion
Godrej Industries Limited's Chemical Business has announced a major expansion initiative as part of its strategic roadmap to become a USD 1 billion global player by 2030. With a planned investment of over ₹750 crore in the coming years, the company is scaling up its manufacturing capabilities across key product categories to meet growing domestic and international demand.
The expansion includes doubling the capacity of Fatty Alcohol and Euric Acid by 35,000 tons and 20,000 tons per annum respectively. The company is also tripling its specialities capacity by adding 21,000 tons annually, while glycerine capacity is being doubled with an additional 24,000 tons. Fermentation capacity is set to rise threefold with 1,500 tons per annum added, and Primary Surfactants production will see an increase of 30,000 tons per annum.
In line with its commitment to sustainability, Godrej Industries will significantly boost its hybrid power infrastructure, aiming to achieve 75% renewable energy usage in its operations. This move aligns with the company's broader focus on Green Chemistry, which includes adopting energy-efficient processes, renewable power, and zero-waste practices.
Godrej is also investing in advanced technologies such as biocatalysis, continuous manufacturing, and fermentation to deliver greener, more efficient, and milder chemical solutions. These initiatives underscore the company's commitment to sustainable growth, innovation, and meeting evolving market needs through environmentally responsible practices.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
U.S. Leads North America Syringe Infusion Pumps Market Amid Rising Hospitalizations and Chronic Diseases
The North America Syringe Infusion Pumps Market is projected to grow from USD 645.1 million in 2024 to USD 1.04 billion by 2030, at a CAGR of 8.40%. Key drivers include an increase in chronic diseases and surgeries, technological advancements, and the expansion of home healthcare. The market is bolstered by favorable regulations and major regional growth. North American Syringe Infusion Pumps Market Dublin, July 04, 2025 (GLOBE NEWSWIRE) -- The "North America Syringe Infusion Pumps Market Size, Share & Trends Analysis Report by Disease Indication (Pediatrics/neonatology, Chemotherapy, Diabetes, Gastroenterology), End-use (Hospitals, Homecare), Country with Growth Forecasts, 2025-2030" report has been added to North America Syringe Infusion Pumps Market was valued at USD 645.1 million in 2024, and is projected to reach USD 1.04 billion by 2030, rising at a CAGR of 8.40%. The market is experiencing substantial growth driven by the increasing prevalence of chronic diseases, affecting approximately six in ten adults and necessitating precise, continuous medication delivery for conditions such as cancer and diabetes. The rising number of surgical procedures and ICU admissions further amplifies demand for these pumps, crucial for delivering anesthetics and critical care medications. This is especially true considering the projected increase in U.S. hospitalizations from 36 million in 2025 to 40 million by advancements in smart infusion technologies, including Dose Error Reduction Systems (DERS) and EHR compatibility, are pivotal in enhancing medication safety and efficiency, as North America leads in their adoption. The expanding home healthcare and ambulatory care sectors, fueled by an aging population and cost-containment strategies, are increasing the demand for portable, user-friendly syringe pumps for safe medication delivery outside hospitals. Favorable regulatory environments and reimbursement policies further support the sustained growth and innovation within the America Syringe Infusion Pumps Market Report Highlights: Pediatrics/neonatology held the largest revenue share of over 25% in 2024, owing to the critical need for precise drug delivery for newborns and infants, coupled with advancements in safety technologies and NICU/PICU investments The chemotherapy segment is projected to grow at the fastest CAGR over the forecast period Market growth is fueled by the critical need for precise syringe pump delivery of potent drugs, supported by safety features, and the increasing number of cancer cases. Hospitals dominated the market with around 40.0% of the total revenue share in 2024 due to high demand for precise drug delivery in critical care and diverse applications. Homecare is projected to grow at the fastest CAGR of 8.7% over the forecast period. The U.S. dominated the North American syringe infusion pumps market, supported by the high prevalence of chronic diseases and growing national healthcare expenditure. Companies Featured The major companies featured in this North America Syringe Infusion Pumps market report include: Baxter B. Braun Medical Inc. Fresenius Kabi AG ICU Medical, Inc. Micrel Medical Devices SA Boston Scientific Corporation BD Terumo Corporation Moog Inc. IRadimed Corporation CODAN Companies ACROMED Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $645.1 Million Forecasted Market Value (USD) by 2030 $1040 Million Compound Annual Growth Rate 8.4% Regions Covered North America Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.3. Competitive InsightsChapter 3. North America Syringe Infusion Pumps Market Variables, Trends & Scope3.1. Market Lineage Outlook3.2. Market Dynamics3.3. North America Syringe Infusion Pumps Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.2. PESTEL AnalysisChapter 4. North America Syringe Infusion Pumps Market: Disease Indication Estimates & Trend Analysis4.1. Disease Indication Segment Dashboard4.2. North America Syringe Infusion Pumps Market: Disease Indication Movement Analysis4.3. North America Syringe Infusion Pumps Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)4.4. Chemotherapy4.5. Diabetes4.6. Gastroenterology4.7. Analgesia/Pain Management4.8. Pediatrics/Neonatology4.9. Hematology4.10. OthersChapter 5. North America Syringe Infusion Pumps Market: End Use Estimates & Trend Analysis5.1. End Use Segment Dashboard5.2. North America Syringe Infusion Pumps Market: End Use Movement Analysis5.3. North America Syringe Infusion Pumps Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)5.4. Hospitals5.5. Homecare5.6. Others (ASC, Nursing Homes, Rehabilitation Centers)Chapter 6. North America Syringe Infusion Pumps Market: Country Estimates & Trend Analysis6.1. Country Market Dashboard6.2. Country Market Share Analysis, 2024 & 20306.3. North America Syringe Infusion Pumps Market by country: Key Takeaways6.4. U.S.6.5. Canada6.6. MexicoChapter 7. Competitive Landscape7.1. Recent Developments & Impact Analysis, By Key Market Participants7.2. Company/Competition Categorization7.3. Vendor Landscape7.3.1. Key company heat map analysis, 20247.4. Company Profiles Baxter B. Braun Medical Inc. Fresenius Kabi AG ICU Medical, Inc. Micrel Medical Devices SA Boston Scientific Corporation BD Terumo Corporation Moog Inc. IRadimed Corporation CODAN Companies ACROMED For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Syringe Infusion Pumps Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Business Upturn
2 hours ago
- Business Upturn
Why are PC Jeweller shares jump 16% today? Details here
By Aman Shukla Published on July 4, 2025, 12:17 IST PC Jeweller shares soared 16% on Friday, touching an intraday high of ₹16.37, after the company reported a robust performance for the quarter ended June 30, 2025. As of 12:16 PM, the shares were trading 14.27% higher at Rs 16.02. In its latest business update, the jewellery retailer revealed an impressive 80% year-on-year growth in standalone revenue, driven by strong wedding and festive demand. Despite the backdrop of fluctuating gold prices, PC Jeweller said it ended the quarter on a 'very strong note,' crediting its operational revamp and improved internal processes for the momentum. The company also highlighted significant progress on the financial front. After slashing its outstanding dues to bankers by over 50% in FY25, PC Jeweller further reduced its debt by 7.5% in Q1 FY26. It has reiterated its commitment to becoming completely debt-free by the end of the current fiscal year. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
2 hours ago
- Business Upturn
BSE shares drop over 7% today; Details here
Shares of BSE Ltd witnessed a sharp decline of over 7% in Friday's trading session, falling as low as ₹2,613.10, down significantly from the previous close of ₹2,820.10. As of 12:23 PM, the shares were trading 5.78% lower at Rs 2,657.00. The stock opened the day at ₹2,778.00 and touched an intraday high at the same level before slipping sharply. Despite the correction, BSE's stock remains up significantly in the long run, having scaled a 52-week high of ₹3,030.00 and far above its 52-week low of ₹705.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
